01
AI Discovery
Generate and prioritize novel molecules across vast chemical spaces.
Computational therapeutics · CNS
Discovering the next generation of medicines for the brain.
MEXIMIA combines artificial intelligence, computational chemistry and quantum technologies to discover novel therapeutics for psychiatric and neurological diseases.
01The challenge
The brain remains one of medicine’s hardest frontiers.
Despite decades of research, developing new treatments for psychiatric and neurological diseases remains slow, expensive and highly uncertain.
Traditional drug discovery struggles to model the complex molecular interactions involved in CNS diseases. MEXIMIA is building a new computational approach.
02Our platform
A new computational engine for drug discovery.
An integrated framework designed to navigate chemical possibility, model molecular behavior, and prioritize the most promising paths forward.
02
Molecular Simulation
Model how candidate compounds interact with biological targets.
03
Quantum Computing
Develop and scientifically benchmark hybrid quantum-classical methods to improve molecular simulations.
03How it works
From target to candidate, one continuous system.
01Target
02Generate
03Simulate
04Rank
05Validate
06Drug Candidate
From biological target to optimized molecule, MEXIMIA integrates computational models to reduce the number of compounds that need to be experimentally tested.
04Initial focus
Starting with diseases of the central nervous system.
MEXIMIA initially focuses on psychiatric and neurological disorders where better molecular understanding and new therapeutic approaches are urgently needed.
01
Psychiatry
02
Neurodegeneration
03
Neuroinflammation
04
Novel CNS targets
05Partnership model
Building medicines with pharmaceutical partners.
MEXIMIA is building a capital-efficient biotech platform combining collaborative discovery programs with proprietary therapeutic assets.
Explore a partnershipDiscovery Partnerships
Collaborative drug-discovery programs using the MEXIMIA platform.
Proprietary Pipeline
Internally generated molecules developed toward licensing and strategic partnerships.
06Founders
Built at the intersection of physics, medicine and technology.
Alexia
PhD in Quantum Computing
Quantum technology and computational science
Melissa
MD, PhD — Psychiatry
Clinical neuroscience and translational medicine
Mike
MD — Radiology
Healthcare entrepreneurship and business development
The future of drug discovery will be computational.
Our mission is to build the computational infrastructure that helps turn previously inaccessible biological questions into new medicines.
07Partner with us
Let’s discover what comes next.
We are looking to collaborate with scientists, biotech companies, pharmaceutical partners and research institutions.